Clinical Trials Logo

B-cell Non-Hodgkin's Lymphoma clinical trials

View clinical trials related to B-cell Non-Hodgkin's Lymphoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06104553 Recruiting - Clinical trials for B-cell Non-Hodgkin's Lymphoma

A Trial of SHR-A1912 Combined With Other Therapies in B-cell Non-Hodgkin 's Lymphoma

Start date: November 17, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

This study aims to evaluate the safety, PK and preliminary anti-tumour activity of SHR-A1912 combined with other therapies in patients with B-cell non-Hodgkin 's lymphoma.

NCT ID: NCT05453669 Recruiting - Clinical trials for B-cell Non-Hodgkin's Lymphoma

Clinical Study of the Efficacy of CD19-CAR-DNT Cells in the Treatment of Relapsed/Refractory B-cell NHL

Start date: June 15, 2022
Phase: Phase 1
Study type: Interventional

To evaluate the safety and tolerability of CD19-CAR-DNT cells infusion in subjects with relapsed/refractory B-cell non-Hodgkin's Lymphoma

NCT ID: NCT05436223 Recruiting - Clinical trials for B-cell Non-Hodgkin's Lymphoma

Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory B-cell Non-Hodgkin's Lymphoma

Start date: August 9, 2021
Phase: Phase 2
Study type: Interventional

A Phase Ⅱ Clinical Study Evaluating the Efficacy and Safety of Human CD19 Targeted T Cells Injection (CD19 CAR-T) Therapy for R/R B-NHL. Patients will be given a conditioning chemotherapy regimen of fludarabine and cyclophosphamide followed by a single infusion of CD19 CAR+ T cells.

NCT ID: NCT05190068 Recruiting - Clinical trials for B-Cell Non-Hodgkin's Lymphoma

HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Start date: January 4, 2022
Phase: Phase 1
Study type: Interventional

A Multicenter, Open-label, Phase I Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of HMPL-760 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

NCT ID: NCT05149391 Recruiting - Clinical trials for B Cell Non-Hodgkin's Lymphoma

A Study of C-CAR039 in Subjects With Relapsed and/or Refractory B Cell Non-Hodgkin's Lymphoma

Start date: July 20, 2021
Phase: Phase 1
Study type: Interventional

This is a single-center, open-label study to evaluate the safety and efficacy of C-CAR039 in relapsed and/or refractory B cell Non-Hodgkin's Lymphoma patients.

NCT ID: NCT04637763 Recruiting - Lymphoma Clinical Trials

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Start date: May 26, 2021
Phase: Phase 1
Study type: Interventional

CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.

NCT ID: NCT03639181 Recruiting - Clinical trials for B-cell Non-Hodgkin's Lymphoma

Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)

Start date: October 15, 2018
Phase: Phase 2
Study type: Interventional

An open-label, single-arm, phase II clinical study of anti-PD-1 antibody GB226 in treatment of recurrent or refractory B-cell non-Hodgkin's lymphoma (B-NHL)

NCT ID: NCT02456207 Recruiting - Clinical trials for B-cell Non Hodgkin's Lymphoma

A Pharmacokinetic Study Comparing SCT400 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma

Start date: May 2015
Phase: Phase 2
Study type: Interventional

The primary objective of the study is to assess the pharmacokinetic (PK) similarity of SCT400 versus rituximab (MabThera®) in patients with CD20+ B-cell Non-Hodgkin's Lymphoma. The secondary objective of the study is to evaluate the pharmacodynamics (PD) and safety of SCT400 versus rituximab (MabThera®), as well as the presence of human anti-chimeric antibodies (HACA).